π¬ BioNTech Pauses Cancer Vaccine Trial Over Safety Concerns
BioNTech has decided to halt its mRNA colorectal cancer vaccine trial following a safety review. This decision impacts the ongoing research conducted by the company. The trial had been underway, and the halt was implemented after a thorough evaluation of safety data. The vaccine aims to help fight colorectal cancer using mRNA technology. Further updates on the trial's future direction are expected from the company soon.